In this study, we evaluated the therapeutic efficacy of recombinant BMP9 in NAFLD mice and found that exogenous supplementation of BMP9 reduced obesity and hepatic steatosis and improved glucose metabolism. This evidence concerns the gene GDF2 and metabolic dysfunction-associated steatotic liver disease.